Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Voyager Therapeut (VYGR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 625,594
  • Shares Outstanding, K 32,617
  • Annual Sales, $ 7,620 K
  • Annual Income, $ -88,290 K
  • 60-Month Beta 2.83
  • Price/Sales 82.75
  • Price/Cash Flow N/A
  • Price/Book 13.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.79
  • Number of Estimates 5
  • High Estimate -0.50
  • Low Estimate -0.94
  • Prior Year -0.63
  • Growth Rate Est. (year over year) -25.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.39 +10.32%
on 03/21/19
22.64 -15.28%
on 04/03/19
+0.28 (+1.48%)
since 03/18/19
3-Month
7.76 +147.16%
on 01/24/19
22.64 -15.28%
on 04/03/19
+10.92 (+132.20%)
since 01/18/19
52-Week
7.76 +147.16%
on 01/24/19
24.24 -20.87%
on 06/27/18
+0.58 (+3.12%)
since 04/18/18

Most Recent Stories

More News
Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy 2019 Annual Meeting

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced multiple data presentations...

VYGR : 19.18 (-0.78%)
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c)(4)

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, granted restricted stock units and a non-qualified...

VYGR : 19.18 (-0.78%)
Voyager Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced management's presentation...

VYGR : 19.18 (-0.78%)
Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson's Disease in the Annals of Neurology

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR) today announced the publication of interim results from the Phase 1b trial of VY-AADC, an investigational gene...

VYGR : 19.18 (-0.78%)
NBIX : 78.43 (-3.34%)
MRI Interventions Announces Collaboration with Voyager Therapeutics for the Design, Manufacture and Supply of V-TAG(TM) Device

MRI Interventions, Inc. (OTCQB:MRIC) a platform neurosurgery company developing products designed to deliver navigation, ablation, deep brain stimulation, aspiration, biopsy and gene therapy today announced...

MRICD : 7.0500 (-2.08%)
VYGR : 19.18 (-0.78%)
MRIC : 2.8400 (-4.70%)
Global Biotech Market Primed for Growth With Renewed Research and Development Efforts

Diseases are commonplace around the world, especially in regions that don't have access to adequate healthcare. They present themselves as various groups such as cancers, diabetes, skin, bacterial, as...

MGNX : 16.21 (-0.86%)
VYGR : 19.18 (-0.78%)
ZLAB : 29.38 (+2.44%)
PRTA : 10.70 (-0.56%)
ABBV : 77.57 (-0.53%)
XBIT : 8.70 (+0.46%)
PBIO : 3.6550 (-3.82%)
IMMU : 16.99 (+2.04%)
AbbVie Extends Deal With Voyager to Make Parkinson's Drugs

AbbVie (ABBV) expands its collaboration with Voyager Therapeutics to develop potential vectorized antibodies for Parkinson's disease (PD) and other synucleinopathies.

VYGR : 19.18 (-0.78%)
JNJ : 137.52 (-0.72%)
ABBV : 77.57 (-0.53%)
RHHBY : 32.6900 (-0.09%)
AbbVie and Voyager Therapeutics Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson's Disease and Other Synucleinopathies

AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological...

VYGR : 19.18 (-0.78%)
ABBV : 77.57 (-0.53%)
Voyager Therapeutics and AbbVie Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson's Disease and Other Synucleinopathies

Deal expands collaborative efforts on vectorized antibodies to target pathological species of alpha-synuclein

VYGR : 19.18 (-0.78%)
ABBV : 77.57 (-0.53%)
Voyager Therapeutics to Present at Upcoming Investor Conferences

Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced management's presentation...

VYGR : 19.18 (-0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade VYGR with:

Business Summary

Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs...

See More

Key Turning Points

2nd Resistance Point 20.32
1st Resistance Point 19.75
Last Price 19.18
1st Support Level 18.67
2nd Support Level 18.16

See More

52-Week High 24.24
Last Price 19.18
Fibonacci 61.8% 17.94
Fibonacci 50% 16.00
Fibonacci 38.2% 14.06
52-Week Low 7.76

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar